Innovent Biologics, Inc. (1801.HK) is in Healthcare, Biotechnology, based in China, listed on HKSE. Market cap 161.57B HKD. 52-week range 69.55 to 112.70 HKD. Trailing P/E 121.9. Data as of 2026-10-09.
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (sintilimab injection), ...